1.Should antiplatelet therapy be continued after intracerebral hemorrhage?
International Journal of Cerebrovascular Diseases 2015;(2):151-155
Duetothepatientswithintracerebralhemorrhageusualypresenttheriskfactorsfor ischemic stroke, the survivors after intracerebral hemorrhage are usualy facing a high risk of recurrent intracerebral hemorrhage or ischemic stroke at the same time. There is alw ays controversy about w hether these patients should be treated w ith antiplatelet therapy. This article introduces the different point of view s of researchers.
2.Is intensive medical therapy alone enough in patients w ith severe symptomatic carotid stenosis?
International Journal of Cerebrovascular Diseases 2015;(6):474-479,480
Thisarticleintroducesthedifferentperspectivesonwhetherusingcarotidendarterectomy or intensifying the optimal medical therapy alone in recurrent stroke prevention practice in patients w ith symptomatic carotid stenosis.
3.Clinical Efficacy of Nalmefene Hydrochloride in the Treatment of Patients with Traumatic Shock
Yudong MA ; Guoyou ZU ; Xingna LI
China Pharmacist 2017;20(1):118-120
Objective: To investigate the clinical efficacy of nalmefene hydrochloride in the treatment of patients with traumatic shock. Methods:Totally 62 cases of patients with traumatic shock were randomly divided into nalmefene treatment group (n=31) and the control group ( n =31 ) according to the random number table. The control group was given the conventional treatment, while nalmefene treatment group was treated with nalmefene hydrochloride additionally. The changes of hemodynamics, plasma TNF-αand vas-cular endothelial function index were compared between the groups. Results:The mean arterial pressure in 24h after the treatment signifi-cantly decreased when compared with that in 12h after the treatment of nalmefene treatment group, and the difference was statistically sig-nificant (P<0. 05);the heart rate in 12h and 24h after the treatment in nalmefene treatment group significantly decreased when com-pared with that before the treatment, and the differences were statistically significant (P<0. 05);the plasma TNF-αlevels in 24h after the treatment in nalmefene treatment group significantly decreased when compared with that in 12h after the treatment, and the difference was statistically significant (P<0. 05), and there was no significant difference in plasma TNF-α levels before the treatment and in 12h after the treatment (P<0. 05);the plasma NO and ET in 24h after the treatment in nalmefene treatment group significantly decreased when compared with that in 12h after the treatment, and the difference were statistically significant (P<0. 05);and there was no signifi-cant difference in plasma NO and ET before the treatment and in 24h after the treatment (P<0. 05);abnormality in electrocardiogram, routine blood tests, routine urine and liver and renal function examinations were not found, and no obvious adverse drug reactions were shown during the treatment course. Conclusion:Nalmefene hydrochloride combined with the conventional treatment in the patients with traumatic shock shows striking efficiency with notable effects on hemodynamics ( heart rate and mean arterial pressure) , which can reduce plasma TNF-α, NO and ET levels and shows significant research significance.